Alain P Bourcier¹*, Gilbert Naccache², Laurent Mamy ³ and Denis Havel⁴*

¹Pelvic Floor Rehabilitation Unit - Centre Médical Victor Hugo, Paris, France
¹Urodanamics Unit - Centre Médical Victor Hugo, Paris, France
²Perineum Healthcare - Saint-Maur des Fossés, France
⁴Centre Perineum Healthcare, 68100 Mulhouse

*Corresponding Author: Alain P Bourcier, Pelvic Floor Rehabilitation Unit - Centre Médical Victor Hugo, Paris, France.

Received: December 09, 2024; Published: December 31, 2024

Abstract

An overview of the symptoms, diagnosis and management for overactive bladder syndrome in the female population. Identify the symptoms, risk factors, diagnosis and the different strategies for management of OAB bladder syndrome and provide professional advice in overactive bladder syndrome.

Keywords: Overactive Bladder Syndrome; Conservative Treatment; Pharmacologic Treatment

References

1. Haylen BT., et al. “An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction”. Neurourology and Urodynamics 29 (2010): 4-20.
2. Irwin DE., et al. “Population- based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study”. European Urology 50 (2006): 1306-1314.
3. Leron E., et al. “Overactive Bladder Syndrome: Evaluation and Management”. Current Urology3 (2008): 117-125.
4. Scarneciu I., et al. “Overactive bladder: A review and update”. Experimental and Therapeutic Medicine 6 (2021): 1444.
5. Wein AJ and Rackley RR. “Overactive bladder: a better understanding of pathophysiology, diagnosis and management”. Journal of Urology 175 (2006): S5-10.
6. Gormley EA., et al. “Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline”. Journal of Urology 188 (2012): 2455.
7. Raju R., et al. “Evaluation and Treatment of Overactive Bladder in Women”. Mayo Clinic Proceedings2 (2020): 370-377.
8. Lightner DJ., et al. “Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment”. Journal of Urology 202 (2019): 558-563.
9. Cameron AP., et al. “The AUA/SUFU guideline on the diagnosis and treatment of idiopathic overactive bladder”. Journal of Urology (2024).
10. Lohsiriwat S., et al. “Effect of caffeine on bladder function in patients with overactive bladder symptoms”. Urology Annals 3 (2011): 14-18.
11. Dallosso HM., et al. “The association of diet and other lifestyle factors with overactive bladder and stress incontinence: a longitudinal study in women”. BJU International 92 (2003): 69-77.
12. Newman DK. “Lifestyle Interventions”. In Pelvic Floor Disorders by Bourcier AP., McGuire, EJ., Abrams Paul (eds). Elsevier Saunders (2004): 269-277.
13. Newman DK., et al. “Structured behavioral treatment research protocol for women with mixed urinary incontinence and overactive bladder symptoms”. Neurourology and Urodynamics 37 (2018): 14-26.
14. Alwis US., et al. “Dietary considerations in the evaluation and management of nocturia”. F1000 Research 9 (2020): F Rev-165.
15. Bourcier A and Juras J. “Behavioral Modification and Conservative Management of Overactive Bladder and Underactive Bladder Disorders”. In: “Female Genitourinary and Pelvic Floor Reconstruction” Martins FE, Veiby Holm H, Sandhu JS, Mc Cammon KA (eds)Online: 09 November (2023): 221-253.
16. Middleton KR., et al. “Long-Term Adherence to Health Behavior Change”. American Journal of Lifestyle Medicine 6 (2003): 395-404.
17. Di Benedetto P., et al. “Rationale of pelvic floor muscles training in women with urinary incontinence”. Minerva Ginecology 60 (2008): 529-541.
18. Dumoulin C., et al. “Pelvic floor muscle training versus no treatment, or inactive control treatments, for urinary incontinence in women”. Cochrane Database System Review10 (2023).
19. Shafik A. “A study on the continence mechanism of the external urethral sphincter with identification of the voluntary urinary inhibition reflex”. Journal of Urology6 (1999): 1967-1971.
20. Burgio KL., et al. “Behavioral training with and without biofeedback in the treatment of urge incontinence in older women: a randomized controlled trial”. JAMA 288 (2002): 2293-2299.
21. Bourcier AP and Burgio KL. “Biofeedback Therapy”. In: Pelvic Floor Disorders by Bourcier AP, McGuire EJ. Abrams P. (eds) (2004): 297-311.
22. Fitz FF., et al. “Ability to contract the pelvic floor muscles and association with muscle function in incontinent women”. International Urogynecology Journal11 (2020): 2337-2344.
23. Herrolen S., et al. “Pudendal nerve stimulation for treatment of lower urinary tract symptoms: A systematic review of safety, technical feasibility and clinical efficacy”. Continence ICS 11 (2024): 101685.
24. Coolen RL., et al. “Electrical stimulation in the treatment of bladder dysfunction: technology update”. Med Devices (Auckl)12 (2019): 337-345.
25. Goldberg RP., et al. “Extracorporeal Electromagnetic Stimulation Therapy”. In: Pelvic Floor Disorders In: Bourcier AP, McGuire EJ. Abrams P. (eds). Elsevier (2004): 291-296.
26. Anrié A., et al. “Magnetic stimulation in the treatment of female urgency urinary incontinence: a systematic review”. International Urogynecology Journal8 (2023): 1669-1676.
27. Michel MC., et al. “Current and emerging pharmacological targets and treatments of urinary incontinence and related disorders”. Pharmacological Reviews (2023), PHARMREV-AR-2021-000523 (2023).
28. Stoniute A., et al. “Effectiveness of anticholinergic drugs for treating people with overactive bladder syndrome”. Cochrane Database of Systematic Reviews 5 (2023).
29. Mirzaei M., et al. “Evaluation of the Clinical Efficacy and Complications of Duloxetine in Comparison to Solifenacin in the Treatment of Overactive Bladder Disease in Women: A Randomized Clinical Trial”. Urology Journal5 (2021): 543-548.
30. Ou YC., et al. “Intravesical Injection of Botulinum Toxin Type A in Patients with Refractory Overactive Bladder-Results between Young and Elderly Populations, and Factors Associated with Unfavorable Outcomes”. Toxins (Basel)2 (2023): 95.
31. De Wachter S., et al. “Sacral Neuromodulation: Mechanism of Action”. European Urology Focus5 (2020).
32. Perroui-Verbe MA and Van Kerrebroeck PEV. “The future of neuromodulation for functional pelvic problems”. Continence 11 (2024): 101694.
33. Cheng KC., et al. “Augmentation cystoplasty: urodynamic and metabolic outcomes at 10-year follow-up”. International Journal of Urology 22 (2015): 1149-1154.

Citation

Citation: Alain P Bourcier., et al. “Overactive Bladder: Causes, Investigations and Management" Acta Scientific Dental Sciences 7.1 (2025): 29-36.

Copyright

Copyright: © 2025 Alain P Bourcier., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.